|
Treatment
| | | |
|
Rt-PA Group
|
110 (48.9%)
|
88 (54.0%)
|
22 (35.5%)
|
|
Heparin only Group
|
115 (51.1%)
|
75 (46.0%)
|
40 (64.5%)
|
|
Age -yr, mean ± SD
|
63.2 (15.9)
|
62.4 (16.6)
|
65.4 (14.0)
|
|
Female sex – no. (%)
|
88 (39.1%)
|
58 (35.6%)
|
30 (48.4%)
|
|
Duration of dialysis –yr, median (IQR)
|
1.0 (0.0 - 6.0)
|
1.0 (0.0 - 6.0)
|
0.0 (0.0 - 1.0)
|
|
Central venous catheter Indication - no. (%):
| | | |
|
Starting dialysis without peripheral access
|
118 (52.4%)
|
84 (51.5%)
|
34 (54.8%)
|
|
Failure of/awaiting peripheral access
|
48 (21.3%)
|
32 (19.6%)
|
16 (25.8%)
|
|
Catheter related infection
|
14 (6.22%)
|
11 (6.75%)
|
3 (4.84%)
|
|
First dialysis catheter ever - no. (%)
|
137 (60.9%)
|
99 (60.7%)
|
38 (61.3%)
|
|
Cause of end-stage renal disease:
| | | |
|
Diabetic nephropathy
|
71 (31.6%)
|
48 (29.4%)
|
23 (37.1%)
|
|
Glomerulonephritis
|
17 (7.56%)
|
12 (7.36%)
|
5 (8.06%)
|
|
Hypertension or vascular disease
|
42 (18.7%)
|
35 (21.5%)
|
7 (11.3%)
|
|
Coexisting or prior illness - no. (%):
| | | |
|
Diabetes mellitus
|
124 (55.1%)
|
86 (52.8%)
|
38 (61.3%)
|
|
Hypertension
|
206 (91.6%)
|
150 (92.0%)
|
56 (90.3%)
|
|
Ischemic heart disease
|
47 (20.9%)
|
34 (20.9%)
|
13 (21.0%)
|
|
Hemoglobin - g/liter, mean ± SD
|
106 (15.7)
|
106 (15.8)
|
106 (15.4)
|
|
Albumin – g/liter, mean ± SD
|
32.1 (6.5)
|
32.1 (6.7)
|
32.0 (5.9)
|
|
Platelet count - x10-9/litre, median (IQR)
|
230 (185–293)
|
233 (185–298)
|
220 (183–283)
|
